caa a22 4500 606156429 CHVBK 20210128100608.0 cr unu---uuuuu 210128e20150301xx s 000 0 eng 10.1007/s10096-014-2269-6 doi (NATIONALLICENCE)springer-10.1007/s10096-014-2269-6 Prior statin use and 90-day mortality in Gram-negative and Gram-positive bloodstream infection: a prospective observational study [Elektronische Daten] [A. Mehl, S. Harthug, S. Lydersen, J. Paulsen, B. Åsvold, E. Solligård, J. Damås, T.-H. Edna] In several studies on patients with bloodstream infection (BSI), prior use of statins has been associated with improved survival. Gram-positive and Gram-negative bacteria alert the innate immune system in different ways. We, therefore, studied whether the relation between prior statin use and 90-day total mortality differed between Gram-positive and Gram-negative BSI. We conducted a prospective observational cohort study of 1,408 adults with BSI admitted to Levanger Hospital between January 1, 2002, and December 31, 2011. Data on the use of statins and other medications at admission, comorbidities, functional status, treatment, and outcome were obtained from the patients' hospital records. The relation of statin use with 90-day mortality differed between Gram-negative and Gram-positive BSI (p-value for interaction 0.01). Among patients with Gram-negative BSI, statin users had significantly lower 90-day total mortality [odds ratio (OR) 0.42, 95 % confidence interval (CI) 0.23-0.75, p = 0.003]. The association remained essentially unchanged after adjusting for the effect of sex, age, functional status before the infection, and underlying diseases that were considered confounders (adjusted OR 0.38, 95 % CI 0.20-0.72, p = 0.003). A similar analysis of patients with Gram-positive BSI showed no association of statin use with mortality (adjusted OR 1.22, 95 % CI 0.69-2.17, p = 0.49). The present study suggests that prior statin use is associated with a lower 90-day total mortality in Gram-negative BSI, but not in Gram-positive BSI. The Author(s), 2014 Mehl A. Department of Medicine, Levanger Hospital, Nord-Trøndelag Hospital Trust, Post Box 333, 7601, Levanger, Norway aut Harthug S. Department of Medicine, Haukeland University Hospital, Bergen, Norway aut Lydersen S. Regional Centre for Child and Youth Mental Health and Child Welfare—Central Norway, Norwegian University of Science and Technology, Trondheim, Norway aut Paulsen J. Department of Medicine, Levanger Hospital, Nord-Trøndelag Hospital Trust, Post Box 333, 7601, Levanger, Norway aut Åsvold B. Department of Public Health, Norwegian University of Science and Technology, Trondheim, Norway aut Solligård E. Clinic of Anesthesia and Intensive Care, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway aut Damås J. Centre of Molecular Inflammation Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway aut Edna T.-H Unit for Applied Clinical Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway aut European Journal of Clinical Microbiology & Infectious Diseases Springer Berlin Heidelberg 34/3(2015-03-01), 609-617 0934-9723 34:3<609 2015 34 10096 https://doi.org/10.1007/s10096-014-2269-6 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10096-014-2269-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Mehl A. Department of Medicine, Levanger Hospital, Nord-Trøndelag Hospital Trust, Post Box 333, 7601, Levanger, Norway aut NATIONALLICENCE 700 1- Harthug S. Department of Medicine, Haukeland University Hospital, Bergen, Norway aut NATIONALLICENCE 700 1- Lydersen S. Regional Centre for Child and Youth Mental Health and Child Welfare—Central Norway, Norwegian University of Science and Technology, Trondheim, Norway aut NATIONALLICENCE 700 1- Paulsen J. Department of Medicine, Levanger Hospital, Nord-Trøndelag Hospital Trust, Post Box 333, 7601, Levanger, Norway aut NATIONALLICENCE 700 1- Åsvold B. Department of Public Health, Norwegian University of Science and Technology, Trondheim, Norway aut NATIONALLICENCE 700 1- Solligård E. Clinic of Anesthesia and Intensive Care, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway aut NATIONALLICENCE 700 1- Damås J. Centre of Molecular Inflammation Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway aut NATIONALLICENCE 700 1- Edna T.-H Unit for Applied Clinical Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway aut NATIONALLICENCE 773 0- European Journal of Clinical Microbiology & Infectious Diseases Springer Berlin Heidelberg 34/3(2015-03-01), 609-617 0934-9723 34:3<609 2015 34 10096